Lipid mobilization with physiological atrial natriuretic peptide concentrations in humans.
BACKGROUND
Atrial natriuretic peptide (ANP) in pharmacological concentrations stimulates lipid mobilization in humans.


OBJECTIVE
The objective was to determine the hemodynamic and metabolic response to physiologically relevant ANP concentrations.


METHODS
The design was a human physiological study, conducted in 2004.


METHODS
The study was conducted at an academic research institute.


METHODS
Fourteen healthy normal-weight men (30 +/- 1.2 yr) participated in the study.


METHODS
Intravenous infusion of human ANP (h-ANP) was administered at rates of 6.25, 12.5, and 25 ng/kg.min.


METHODS
We studied local changes in blood flow and glucose and lipid metabolism of abdominal sc adipose tissue and femoral skeletal muscle by microdialysis. Overall changes in energy expenditure and substrate oxidation rates were monitored by indirect calorimetry.


RESULTS
The increase in serum nonesterified fatty acids and glycerol concentrations were correlated with ANP plasma concentrations (r(2) = 0.86 and r(2) = 0.76, respectively). In adipose tissue, glycerol increased from 53 +/- 6 micromol/liter to 87+/-13 micromol/liter (P < 0.001). In femoral skeletal muscle, glycerol concentrations did not change, whereas lactate-to-pyruvate ratio decreased from 91 +/- 23 to 32 +/- 4 (P < 0.001). Indirect calorimetry indicated an increase in lipid oxidation (P < 0.05) concomitantly with a decrease in carbohydrate oxidation (P < 0.01), without changes in overall energy expenditure.


CONCLUSIONS
ANP briskly stimulates lipid mobilization and oxidation at plasma concentrations that are encountered in conditions such as heart failure. Natriuretic-peptide induced lipid mobilization might contribute to cardiac cachexia. Drugs that interfere with the natriuretic peptide system should be evaluated for potential metabolic side effects.
Birkenfeld
Andreas L
AL
Franz-Volhard Clinical Research Center, Haus 129, Charité Campus Buch, Wiltbergstrasse 50, 13125 Berlin, Germany.
Boschmann
Michael
M
Moro
Cedric
C
Adams
Frauke
F
Heusser
Karsten
K
Franke
Gabriele
G
Berlan
Michel
M
Luft
Friedrich C
FC
Lafontan
Max
M
Jordan
Jens
J
D000273:Adipose Tissue / Q000187:drug effects / Q000378:metabolism; D000328:Adult; D009320:Atrial Natriuretic Factor / Q000008:administration & dosage / Q000494:pharmacology*; D001794:Blood Pressure / Q000187:drug effects; D000431:Ethanol / Q000097:blood; D005230:Fatty Acids, Nonesterified / Q000097:blood; D006439:Hemodynamics; D006801:Humans; D007262:Infusions, Intravenous; D007773:Lactates / Q000097:blood; D008053:Lipid Mobilization / Q000187:drug effects*; D008297:Male; D017551:Microdialysis; D018482:Muscle, Skeletal / Q000187:drug effects / Q000378:metabolism; D012016:Reference Values; D014280:Triglycerides / Q000097:blood
D005230:Fatty Acids, Nonesterified; D007773:Lactates; D014280:Triglycerides; D000431:Ethanol; D009320:Atrial Natriuretic Factor